Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09EUH
|
||||
| Former ID |
DNC003704
|
||||
| Drug Name |
FUTOENONE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H20O5
|
||||
| Canonical SMILES |
CC1C(CC2CC13C=C(C(=O)C=C3O2)OC)C4=CC5=C(C=C4)OCO5
|
||||
| InChI |
1S/C20H20O5/c1-11-14(12-3-4-16-17(5-12)24-10-23-16)6-13-8-20(11)9-18(22-2)15(21)7-19(20)25-13/h3-5,7,9,11,13-14H,6,8,10H2,1-2H3/t11-,13+,14+,20-/m1/s1
|
||||
| InChIKey |
SXHVHWXETMBKPP-KXXATPMCSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Stromelysin-1 | Target Info | Inhibitor | [1] | |
| KEGG Pathway | TNF signaling pathway | ||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL4 Signaling Pathway | |||||
| PANTHER Pathway | Plasminogen activating cascade | ||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Posttranslational regulation of adherens junction stability and dissassembly | ||||
| p75(NTR)-mediated signaling | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| EGFR Transactivation by Gastrin | |||||
| WikiPathways | Activation of Matrix Metalloproteinases | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Oncostatin M Signaling Pathway | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Inhibition of metalloproteinase by futoenone derivatives, Bioorg. Med. Chem. Lett. 5(15):1637-1642 (1995). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.